432 reports of this reaction
3.2% of all EMTRICITABINE reports
#3 most reported adverse reaction
ANXIETY is the #3 most commonly reported adverse reaction for EMTRICITABINE, manufactured by Gilead Sciences, Inc.. There are 432 FDA adverse event reports linking EMTRICITABINE to ANXIETY. This represents approximately 3.2% of all 13,674 adverse event reports for this drug.
Patients taking EMTRICITABINE who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANXIETY is moderately reported among EMTRICITABINE users, representing a notable but not dominant share of adverse events.
In addition to anxiety, the following adverse reactions have been reported for EMTRICITABINE:
The following drugs have also been linked to anxiety in FDA adverse event reports:
ANXIETY has been reported as an adverse event in 432 FDA reports for EMTRICITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANXIETY accounts for approximately 3.2% of all adverse event reports for EMTRICITABINE, making it one of the most commonly reported side effect.
If you experience anxiety while taking EMTRICITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.